217 Diagnostic utility of molecular and imaging biomarkers 2 malignant histology, ni included indeterminate cytology US features analyzed malignant PTC FVPTC FTC FTC-OV MTC other n.s. Bethesda III SN, MA 35% 36 Bethesda III SO, HY, TW, AH, IM, IV, MI, MA 10% 6 Bethesda III AUS SO, HY, SZ, TW, IM, MI, MA 42% 55 9 Thy3 SO, HY, SZ, IM, IV, MA 18% 3 3 1 Bethesda III HY, TW, AH, IM, IV, MI 13% 15 4 Bethesda III other 29% 24 Bethesda IV SZ 14% 14 7 Bethesda IV SO, HY, TW, AH, IM, IV, MI 29% 27781 1 3 Bethesda III SN, SO, HY, SZ, TW, AH, IM, IV, MI, MA 40% 100 Bethesda III SN, SO, HY, SZ, TW, IM, IV, MI, MA 30% 83 Thy3 HY, AH, IM, IV, MI 27% 30 25 26 3 1 Thy3 HY, AH, IM, IV, MI 31% 9 12 8 3 1 Bethesda III TI 39% 16 Bethesda IV SO, SZ, MI 34% 23 11 15 2 Bethesda III or IV TI 27% 24 indeterminate SN, SO, HY, SZ, MI 21% 1 2 3 1 Bethesda III SO, HY, TW, IM, MI, TI 31% 6 7 1 1 3 Bethesda III or IV SN, SO, HY, SZ, TW, AH, IM, MI, MA 31% 6 3 1 1 Bethesda III or IV SO, IM, MI, MA 16% 26 Bethesda III or IV HY, SZ, IM, IV, MI 11% 6 7 1 Bethesda IV HY, TW, IM, MI 35% 16 71 3 TIR 3 SO, HY, IM, IV, MI 21% 13 5 Bethesda III SO, HY, SZ, TW, IM, MI, MA, TI 43% 54177 2 1 1 27.0% 639 285 240 39 11 37 558
RkJQdWJsaXNoZXIy MTk4NDMw